Wegovy
(Semaglutide)

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).

Limitations of Use: Wegovy should not be used along with other semaglutide-containing products or any other GLP-1 receptor agonist. The efficacy and safety of coadministration with certain other products for weight loss have not been established. This medicinal product has not been studied in individuals with a history of pancreatitis.

Recommended Dosage: Wegovy is available in 5 different dose strengths, ranging from 0.25 mg to 2.4 mg. Each dose is supplied in a different color pen. It is administered once weekly. It’s administered on the same day each week, any time of day, with or without food.

Recommended Dosage in Adults: Initiate therapy with a dosage of 0.25 mg injected subcutaneously (SC) once-weekly. Then follow the dose escalation to minimize gastrointestinal side effects. In case patients do not tolerate a dose of Wegovy during dosage escalation, delay the dosage escalation for four weeks. The 0.25 mg, 0.5 mg, and 1 mg once weekly dosages are initiation and escalation dosages and are not authorized as maintenance dosages for chronic weight management. The maintenance dosage in adults is either 2.4 mg (recommended) or 1.7 mg once weekly. Consider therapy response and tolerability when selecting the maintenance dosage.

Recommended Dosage in Pediatric Patients Aged 12 Years and Older: Initiate therapy with a dosage of 0.25 mg injected subcutaneously (SC) once  weekly. Then follow the Wegovy dose escalation to minimize gastrointestinal side effects. The maintenance dosage in pediatric patients aged 12 years and older is 2.4 mg once weekly. 

• Semaglutide reduces blood glucose and can cause hypoglycemia. In patients with T2D, monitor blood glucose before starting and during treatment. When starting treatment, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to scale down the risk of hypoglycemia.
  
• Cases of acute kidney injury and worsening of chronic renal failure may occur. Monitor renal function when starting or escalating doses of Semaglutide injections in those reporting severe adverse gastrointestinal reactions. Monitor renal function in all those with renal impairment reporting any side effects that could cause volume depletion. 
  
• Critical hypersensitivity reactions (e.g., anaphylaxis, angioedema) may occur. If hypersensitivity reactions occur, stop therapy and treat patients immediately. Monitor patients until signs and symptoms resolve. Semaglutide is contraindicated in those with a prior serious hypersensitivity reaction to it or any of the excipients in the medicine.
  
• Anaphylaxis and angioedema may occur with other GLP-1 receptor agonists. Use caution in a patient with a known history of anaphylaxis or angioedema with another GLP-1 receptor agonist because it is not known whether such patients will be predisposed to these reactions with the medicine Semaglutide.
  
• Monitor heart rate at regular intervals. Patients should inform their clinician of palpitations or feelings of a racing heartbeat while at rest during Semaglutide treatment. If patients experience a sustained increase in resting heart rate, discontinue treatment with Semaglutide. 
  
• Suicidal behavior and ideation may occur with other weight management products. Monitor patients treated with semaglutide for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue treatment in those who experience suicidal thoughts or behaviors.
  

What documents are required to import WEGOVY to India?

WEGOVY (semaglutide) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

WEGOVY (semaglutide injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Wegovy in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of WEGOVY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Wegovy injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the WEGOVY (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Wegovy®?

Semaglutide is a Generic Name for the trade name drug Wegovy®.

What is the Manufacturer’s Name of Wegovy®?

Wegovy® is manufactured by Novo Nordisk.

Is Wegovy® approved by the FDA?

Yes, Wegovy® is approved by the FDA. Date of first approval: June 4, 2021.

Where can I get Wegovy® at the best price in India?

To get the best Wegovy price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Wegovy®, a medical prescription is needed from a treating physician.

What is the dosage and form of Wegovy® supplied?

Wegovy® is supplied as injections: a pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg for subcutaneous use. 

What are the most common side effects of Wegovy®? 

The most common side effects of Wegovy® are vomiting, nausea, diarrhea, constipation, abdominal pain, abdominal distension, headache, fatigue, dyspepsia, dizziness, eructation, hypoglycemia in patients with type 2 diabetes (T2D), gastroesophageal reflux disease, flatulence, gastroenteritis, and nasopharyngitis. 

How much does Wegovy® cost in India?

The cost of Wegovy in India can vary. To procure this GLP-1 receptor agonist legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Wegovy®?

Store the single-dose pen in the refrigerator from 2-8°C (36-46°F). If needed, before cap removal, the pen can be kept from 8-30°C (46-86°F) for up to 28 days. Do not freeze. Protect it from light. It must be kept in the original carton until the time of administration. Discard the pen after use. 

Is it safe to buy Wegovy® online in India?

Yes, one can buy Wegovy online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Wegovy® through legal channels.